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        Lipoxins (LXs) are trihydroxytetraene-containing 
arachidonic acid mediators that down-modulate 
and promote the resolution of infl  ammatory 
processes (  1  –  7  ). LXs play a key counterregula-
tory role in mouse models of infection with 
  Mycobacterium tuberculosis   and   Toxoplasma gon-
dii   (  1  –  3, 7  ). Similarly, defi  cient LX-mediated 
counterregulation has been linked to the patho-
genesis of infl  ammatory diseases, such as severe 
asthma (  8  ), cystic fi  brosis lung disease (  3  ), and 
periodontal disease (  7  ). The benefi  cial eff  ects 
of LX analogue administration in diverse ro-
dent models of infl  ammatory pathology, along 
with the observation that administration of the 
widely used antiinfl  ammatory drug ASA leads to 
the generation of metabolically more stable LX 
carbon 15-epimers (ASA-triggered LX [ATL]), 
has suggested therapeutic promise for specifi  c 
harnessing of the biological activities of these po-
tent lipid mediators. However, their molecular 
mechanisms of action remain underdefi  ned. 
  We recently showed that suppressor of cyto-
kine signaling (SOCS) 2 is a crucial intracel-
lular mediator of the antiinfl  ammatory actions 
of LX and ATL in vivo during   T. gondii   infec-
tion (  9  ). SOCS proteins are known to inhibit 
receptor-mediated signal transduction via sev-
eral pathways, including inhibition of tyrosine 
phosphorylation by allosteric blockage (e.g., 
of JAK proteins) and induction of proteasomal 
degradation through promoting polyubiqui-
tylation (e.g., of STAT proteins) (  10  ). Our 
studies were aimed at defi  ning the molecular 
targets and mechanisms of action of LX- and 
ATL-induced SOCS2. The results presented in 
this study demonstrate that LX and ATL in-
duce SOCS2-dependent ubiquitinylation and 
proteasomal degradation of TNF receptor –  asso-
ciated factor (TRAF) 2 and TRAF6, inhibiting 
DC production of proinfl  ammatory cytokines. 
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  Innate immune signaling is critical for the development of protective immunity. Such 
signaling is, perforce, tightly controlled. Lipoxins (LXs) are eicosanoid mediators that play 
key counterregulatory roles during infection. The molecular mechanisms underlying LX-
mediated control of innate immune signaling are of interest. In this study, we show that LX 
and aspirin (ASA)-triggered LX (ATL) inhibit innate immune signaling by inducing suppres-
sor of cytokine signaling (SOCS) 2  –  dependent ubiquitinylation and proteasome-mediated 
degradation of TNF receptor  –  associated factor (TRAF) 2 and TRAF6, which are adaptor 
molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members to 
intracellular signaling events. LX-mediated degradation of TRAF6 inhibits proinfl  ammatory 
cytokine production by dendritic cells. This restraint of innate immune signaling can be 
ablated by inhibition of proteasome function. In vivo, this leads to dysregulated immune 
responses, accompanied by increased mortality during infection. Proteasomal degradation 
of TRAF6 is a central mechanism underlying LX-driven immune counterregulation, 
and a hitherto unappreciated mechanism of action of ASA. These fi  ndings suggest a 
new molecular target for drug development for diseases marked by dysregulated infl  am-
matory responses. 1078 TRAF2 AND TRAF6 PROTEASOMAL DEGRADATION BY LIPOXIN-INDUCED SOCS2 | Machado et al.
    RESULTS   
  LX-induced SOCS2 physically interacts with TRAF2 
and TRAF6 
  Given that LX-induced SOCS2 is a physiological modula-
tor of Toll-like receptor (TLR)  –  dependent innate immune 
recognition of   T. gondii  , we examined whether LX-induced 
SOCS2 interacted specifi  cally with conserved signaling elements 
Further, these results indicate that the proteosome-dependent 
pathway of modulating innate immune signaling aff  ected by 
LX and ATL is critical for restraining in vivo infl  ammatory 
responses during infection with   T. gondii  . Our fi  ndings elucidate 
a previously unappreciated mechanism of action of ASA, and 
suggest a new molecular target for drug development for diseases 
caused or exacerbated by dysregulated infl  ammatory responses. 
    Figure 1.         LX-induced SOCS2 physically interacts with TRAF2 and TRAF6, inhibiting proinfl  ammatory cytokine expression by DCs.  
(A) Splenic DCs were incubated with 1   μ  g/ml LXA  4   or 100 ng/ml IL-10 or media control (CT) for 6 or 12 h. SOCS2 or SOCS1 was immunoprecipitated 
(I.P.) from whole-cell lysates, followed by Western blot analysis of immunoprecipitates and total cell lysates to quantify SOCS1, SOCS2, TRAF1-6, IRAK4, 
MyD88, and actin expression. (B) DCs from WT or SOCS2-defi  cient mice were exposed to 1   μ  g/ml LXA  4   or vehicle for 6 h, followed by stimulation with 
IL-1    , TNF (both at 100 ng/ml), CD40L, STAg, LPS, or CpG-oligonucleotides (all at 1   μ  g/ml). 4 h later, mRNA was purifi  ed and real-time RT-PCR was used 
to quantify TNF, IL-6, IL-12p40, and IFN-     mRNA expression. Data shown are the mean (  ±   the SD) of triplicate samples, and are representative of at 
least two independent experiments with similar results. Asterisks indicate statistically signifi  cant differences between SOCS2-defi  cient and WT control 
mice (P   <   0.05).     JEM VOL. 205, May 12, 2008 
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  SOCS2 targeting of TRAF2 and TRAF6 inhibits 
proinfl  ammatory cytokine production by DCs 
  TRAFs serve as critical adaptor molecules in signaling cas-
cades downstream of receptors in the TNF and IL-1 receptor 
families of receptors, as well as TLRs (  11  –  13  ). TRAF2 and 
TRAF6 regulate the transcription of downstream target genes 
via activation of the c-Jun N-terminal kinase (JNK) and NF-
    B signaling pathways (  14  –  19  ). Notably, TRAF6-defi  cient 
mice fail to produce IL-12 in response to microbial stimuli 
(  19  ). To examine the functional consequences of LXA  4  -
stimulated SOCS2  –  TRAF interactions during DC activa-
tion, WT and SOCS2-defi  cient mouse splenic DCs were 
downstream of the TLRs. Purified splenic DCs (    90% 
CD11c  +  ) were incubated with LXA  4   (or IL-10, which acti-
vates SOCS1 and SOCS3, as a control), and coimmunopre-
cipitation techniques were used to defi  ne specifi  c interactions 
of TLR signaling intermediates with SOCS1 and SOCS2. 
As shown in   Fig. 1 A  , immunoprecipitation of SOCS2, 
but not SOCS1, from LXA  4  -treated DCs led to specifi  c co-
precipitation of TRAF6 and TRAF2, but not MyD88, 
IRAK4, or any of the other TRAFs.   This specifi  city among 
TRAFs is notable. SOCS interacts with SH2 domains on 
other proteins (  10  ), which are present on all members of the 
TRAF family. 
    Figure 2.         SOCS2 targets TRAF2 and TRAF6 for proteasomal degradation.   (A) WT and SOCS2-defi  cient splenic DCs were treated with LXA  4   (at  con-
centrations ranging from 10 to 1,000 ng/ml) for 20 h, or were treated with LXA  4   or IL-10 (at 100 ng/ml times ranging from 1 to 20 h), followed by quanti-
fi  cation of TRAF6 and actin expression by Western blot. (B) DCs from WT and SOCS2-defi  cient mice were treated with 2   μ  M lactacystin or medium alone, 
1 h before incubation with 1   μ  g/ml LXA  4  . At the indicated times, whole-cell extracts were prepared and TRAF2, TRAF6, ERK2, p38, JNK2, I   B   , and actin 
expression was quantifi  ed by immunoblot analysis. (C) DCs from WT and SOCS2-defi  cient mice were incubated with 1   μ  g/ml LXA  4  . At the indicated times, 
whole-cell extracts were immunoprecipitated with antibodies to ubiquitin, TRAF2, or TRAF6, followed by Western blot analysis using antibodies to TRAF2, 
TRAF6, or polyubiquitin (clone FK1). (D) WT and SOCS2-defi  cient DCs were treated with 2   μ  M lactacystin or vehicle for 1 h. DCs were subsequently incu-
bated with 1   μ  g/ml LXA  4  or vehicle for 8 h, followed by stimulation with 100 ng/ml STAg for 24 h. IL-12 p70 levels were quantifi  ed by ELISA in culture 
supernatants. Data shown represent the means   ±   the SD of triplicate samples and are representative of at least two independent experiments with similar 
results. *, P   <   0.01, PBS versus inhibitor treatment.     1080 TRAF2 AND TRAF6 PROTEASOMAL DEGRADATION BY LIPOXIN-INDUCED SOCS2 | Machado et al.
TRAF6 in DCs (  Fig. 2 C  ). Thus, as might be expected, bio-
chemical inhibition of proteasome activity with lactacystin 
led to parallel ablation of both LX-induced, SOCS2-de-
pendent TRAF2/6 degradation and LX-induced, SOCS2-
dependent inhibition of TLR-driven cytokine production in 
DCs (  Fig. 2, B and D  ). The fact that treatment of SOCS2-
defi  cient DCs with lactacystin failed to alter TRAF levels and 
IL-12 production (  Fig. 2, B and D  ) suggests little toxicity for 
this inhibitor under these conditions. Collectively, these data 
suggest that these LX-mediated antiinfl  ammatory actions are 
dependent on SOCS2-induced TRAF2 and TRAF6 protea-
somal degradation. 
  Restoration of TRAF6 expression overcomes LX-mediated 
modulation of myeloid cell cytokine production 
  To directly defi  ne the roles of TRAF2 and TRAF6 as down-
stream targets for LX-mediated antiinfl  ammatory activity, we 
analyzed the ability of LXA  4   to inhibit IL-12 and TNF pro-
duction in response to TLR or TNFR stimulation after 
overexpression of TRAF2, TRAF3, or TRAF6 in a mouse 
macrophage cell line (RAW264.7). As shown in   Fig. 3 A  , 
TRAF2 and TRAF6 overexpression overcame LX-depen-
dent degradation.   Only overexpression of TRAF6, but not 
TRAF2 or 3, reversed LX-induced inhibition of IL-12 and 
TNF production after TNFR/TLR stimulation (  Fig. 3 B  ; 
  Table I  ; Fig. S1, A [Table I] and B [Table II and III], available 
at http://www.jem.org/cgi/content/full/jem.20072416/DC1).  
Thus, SOCS2-mediated degradation of TRAF6 is essen-
tial to LX-mediated inhibition of proinfl  ammatory cyto-
kine production. 
treated with LXA  4   and stimulated with IL-1    , TNF, CD40L, 
LPS, CpG-oligonucleotides, or soluble   T. gondii   tachyzoite 
antigen (STAg). Exposure to LXA  4   strongly blocked the ex-
pression of IL-6, TNF-    , IL-12, and IFN-     in WT but not 
SOCS2-defi  cient DCs, regardless of the stimulus (  Fig. 1 B  ). 
Thus, LX-induced SOCS2 inhibits biological responses known 
to be dependent on TRAF2/6, suggesting that these adaptors 
are functional targets of SOCS2-dependent modulation of 
proinfl  ammatory responses. 
  SOCS2 targets TRAF2 and TRAF6 
for proteasomal degradation 
  SOCS proteins mediate their actions by docking to the intra-
cellular domains of pattern recognition, cytokine, or hormone 
receptors (thereby preventing interactions with downstream 
signaling elements), or by ubiquitinylation and proteasome-
dependent degradation of signaling intermediates (  10, 20  –  22  ). 
To analyze the latter possibility, we quantifi  ed the stability 
of TRAF2/6 in LXA  4  -exposed (or IL-10  –  exposed) DCs. 
As shown in   Fig. 2 (A and B)  , exposure to LXA  4  , but not 
IL-10, led to a SOCS2-dependent reduction in the amount 
of TRAF2 and TRAF6 protein expression as early as 5 h 
after exposure, whereas the expression levels of related signal-
ing intermediates, including ERK2, JNK2, p38, and I    B     
were not altered.   Notably, LXA  4   exposure led to SOCS2-
dependent polyubiquitylation of TRAF2 and TRAF6 (  Fig. 
2 C  ). Also, it is important to note that the reciprocal im-
mune precipitation of TRAF2/6, followed by Western blot 
for polyubiquitin chain, revealed a similar pattern of LX-
induced SOCS2-dependent polyubiquitylation of TRAF2 and 
    Figure 3.         Restoration of TRAF expression overcomes LX-mediated modulation of myeloid cell cytokine production.   (A) RAW 264.7 cells were 
transfected with TRAF2, TRAF3, TRAF6, or control plasmids, followed by quantifi  cation of TRAF2, TRAF3, TRAF6, and actin by Western blot. RAW 264.7 
cells, transfected and treated with LXA  4   as noted in B, were stimulated with TNF (100 ng/ml), CD40L, STAg or LPS (all at 1   μ  g/ml). 24 h later, IL-12p70 was 
quantifi  ed by FACS. Data shown represent the means   ±   the SD of triplicate samples and are representative of at least two independent experiments with 
similar results. *, P   <   0.01, PBS versus LX treatment.     JEM VOL. 205, May 12, 2008 
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starting at day 11, which was previously found to be the time 
at which increases in serum levels of LXA  4   are detectable. At 
this time point, most T cell priming is thought to have oc-
curred. Moreover, direct testing of the eff  ect of proteasome 
inhibition on CD8  +   T cell during LCMV infection showed 
that such treatment did not aff  ect expansion of CD8  +   T cells 
specifi  c for LCMV-derived peptides (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20072416/DC1). As 
shown in   Fig. 5 A  , proteasome inhibition during   T. gondii   
infection mirrored the uncontrolled proinfl  ammatory pheno-
type seen in both 5-LO  –   and SOCS2-defi  cient mouse strains 
(  9, 26  ), including: (a) high levels of systemic (  Fig. 5, A and B  ) and 
tissue (Figs. S3  –  S5) proinfl  ammatory cytokine production; 
(b) more effi   cient control of parasite burden (  Fig. 5 E  ); and 
  Proteasome inhibition abolishes the in vivo 
antiinfl  ammatory actions of LX-stimulated SOCS2: 
modulation of proinfl  ammatory responses 
to microbial challenge 
  To assess the in vivo relevance of LX-induced, SOCS2-de-
pendent TRAF6 proteasomal degradation, we moved to 
an in vivo model of LX-dependent inhibition of DC IL-12 
production, termed   “  DC paralysis  ”   (  23  ). In this system, in-
jection of STAg causes endogenous generation of LXA  4   
that, in turn, inhibits IL-12 production by DCs during sub-
sequent rechallenge (  Fig. 4 A  ).   As noted previously, DC pa-
ralysis is SOCS2-dependent; SOCS2-defi  cient mice produce 
equivalent amounts of IL-12 regardless of previous STAg 
challenges (  Fig. 4 A  ) (  9  ). Importantly, mice treated with lac-
tacystin or another proteasome inhibitor, PR-11 (  24  ), failed 
to exhibit DC paralysis, producing equivalent levels of IL-12 
as single STAg-injected WT mice (  Fig. 4 A  ). Moreover, 
neither lactacystin nor PR11 treatment aff  ected IL-12 pro-
duction in STAg-injected SOCS2-defi  cient mice, excluding 
the possibility of unrelated nonspecifi  c eff  ects after in vivo 
proteasome inhibition. IL-10  –  defi  cient mice suff  er acute mor-
tality caused by uncontrolled infl  ammation during   T. gondii   
infection (  25  ). The induction of DC paralysis rescues IL-10  –
  defi  cient mice from such mortality (  25  ). Notably, pretreatment 
with the proteasome inhibitor PR11 before DC paralysis 
ablated the protective eff  ects of STAg-induced DC paraly-
sis in IL-10  –  defi  cient mice (  Fig. 4 B  ). Thus, the protective ac-
tions of LX-stimulated DC paralysis during   T. gondii   infection 
are mediated in a proteasome-dependent manner that corre-
lates with SOCS2-driven proteasome-mediated degradation 
of TRAF6. 
  In vivo proteasome inhibition abolishes 
the antiinfl  ammatory actions of LX-stimulated SOCS2: 
modulation of proinfl  ammatory responses during infection 
  Endogenously generated LXs control proinfl  ammatory re-
sponses through SOCS2 during   T. gondii   and   M. tuberculosis   
infection (  2, 26  ). In the absence of LXs or SOCS2, infection 
with   T. gondii   is lethal because of aberrant, uncontrolled in-
fl  ammation (  26  ). To analyze whether proteasomal degradation 
of TRAF2 and TRAF6 are downstream targets for LX-me-
diated control of proinfl  ammatory responses during in vivo 
infection, we infected WT and SOCS2-defi  cient mice with 
  T. gondii  , in the presence or absence of treatment with PR11 
    Table I  .  Restoration of TRAF expression overcomes LX-mediated modulation of myeloid cell cytokine production 
GFP  +  IL12  +   (%) PBS LPS LPS  +  LXA CD40L CD40L  +  LXA TNF TNF  +  LXA STAg STAg  +  LXA
Empty Vector 1.5   ±   0.18 7.48   ±   0.9 3.82   ±   0.41 8   ±   0.87 4.32   ±   0.36 9.12   ±   0.97 4.47   ±   0.58 11   ±   1.4 5.82   ±   0.9
TRAF2 2   ±   0.31 8.88   ±   1 3.73   ±   0.47 6.37   ±   0.59 3.36   ±   0.49 9.4   ±   0.89 5.5   ±   0.63 12.7   ±   1.5 8   ±   0.92
TRAF3 1.8   ±   0.4 15   ±   2.1 8.91   ±   0.9 10.3   ±   1.5 6.36   ±   0.9 16.5   ±   2.9 12.38   ±   1.2 12.5   ±   2 7.23   ±   2.8
TRAF6 1.6   ±   1 11.4   ±   2.2 10.4   ±   0.8 10.7   ±   1.9 9.83   ±   1.4 12   ±   2.5 11.3   ±   1.7 13.8   ±   2.1 12.18   ±   1.7
10  7   RAW 264.7 cells were transfected with mTRAF6, fl  ag-tagged mTRAF2, fl  ag-tagged mTRAF3, or the respective control plasmids (10   μ  g), followed by incubation in 24-well 
plates for 15 h. Cells were then exposed to LXA  4   (1   μ  g/ml) or vehicle, and incubated for a further 24 h before stimulation with LPS, CD40L, STAg (all at 1   μ  g/ml), and TNF (at 
100 ng/ml). IL-12 p70 expression was subsequently quantifi  ed by FACS.
    Figure 4.         In vivo proteasome inhibition abolishes the antiinfl  am-
matory actions of LX-induced SOCS2; inhibition of microbial prod-
uct challenge.   (A) WT and SOCS2-defi  cient mice (  n   = 5 mice/group) were 
injected intraperitoneally with 0.2 ml/mouse PBS, 20 mg/kg lactacystin, 
or 0.2 mg/kg PR11. 1 h later, animals were challenged with PBS or STAg 
(5   μ  g/mouse). 24 h later, mice were rechallenged with STAg. 6 h later, splenic 
DCs were harvested, purifi  ed, and cultured overnight to allow for sponta-
neous cytokine release. IL-12p70 secretion was quantifi  ed by ELISA. (B) IL-
10 – defi  cient mice (  n   = 5 mice/group) were injected intraperitoneally with 
PBS (0.2 ml/mouse) or PR11 (0.2 mg/Kg), and after 1 h, with PBS or STAg 
(5   μ  g/ml). 24 h later, mice were infected intraperitoneally with 20 cysts of 
  T. gondii   (ME49 strain). 5 and 7 d after infection, serum concentrations of 
IL-12 p70 and IFN-     were  quantifi  ed by ELISA; mortality was monitored 
over time. Graphed values represent the means   ±   the SD. The experiments 
shown are representative of at least two independent experiments yield-
ing similar results.     1082 TRAF2 AND TRAF6 PROTEASOMAL DEGRADATION BY LIPOXIN-INDUCED SOCS2 | Machado et al.
reversed by PR11 treatment (  Fig. 5 G   and Figs. S6  –  S9). It is 
important to emphasize that proteasomal inhibition did not 
aff  ect STAg-driven proinfl  ammatory responses in SOCS2-
defi  cient mice and DCs, suggesting that the phenotype seen 
in WT mice is not derived from unrelated actions by the drug. 
Collectively, these data clearly establish TRAF2 and TRAF6 
as critical downstream targets for proteasomal degradation 
mediated by LX-stimulated SOCS2. Thus, LX-mediated 
degradation of these key proinfl  ammatory signaling adaptor 
proteins is essential for tight control of the innate immune 
response to infection with   T. gondii  . 
  The antiinfl  ammatory actions of ATLs require SOCS2-
dependent proteasomal degradation of TRAF2 and TRAF6 
  The benefi  cial biological eff  ects of in vivo ASA administra-
tion occur, in part, through the generation of endogenous 
ATL. Our data at this juncture suggested that ATL-stimu-
lated, SOCS2-mediated, proteasome-dependent degradation 
of TRAF proteins is mechanistically important for ASA-driven 
modulation of proinfl  ammatory cytokine production. Indeed, 
similar to the eff  ects of LXA  4   exposure, in vivo exposure of 
DCs to ASA led to SOCS2-independent ATL generation 
(Fig. S10 A, available at http://www.jem.org/cgi/content/
full/jem.20072416/DC1), along with a SOCS2-dependent 
specifi  c decrease in DC expression of TRAF6 and TRAF2 
(  Fig. 6 A  ).   LPS treatment alone did not change baseline levels 
of signaling molecules either in WT or SOCS2-defi  cient 
DCs, except for the expected decrease in I    B     (  Fig. 6 A  ) 
(  24  ). ASA treatment before LPS exposure delayed the appear-
ance of phosphorylated ERK1/2 and p38 in WT, but not in 
SOCS2-defi  cient, DCs (  Fig. 6 A  ). Consistent with fi  ndings 
in cells exposed to ASA alone, TRAF2 and TRAF6 ex-
pression was decreased in LPS-stimulated, ASA-treated WT, 
but not SOCS2-defi  cient, DCs. Finally, LPS-induced I    B     
degradation was prevented by ASA treatment in a SOCS2-
dependent manner (  Fig. 6 A  ). Although the cause-eff  ect rela-
tionship is likely to be indirect, the delay in the generation of 
15-epi-LX in aspirin (ASA)-treated, COX1-defi  cient mice 
indicated that both SOCS2 induction and TRAF6 degra-
dation are dependent on the endogenous generation of 15-
epi-LX (  Fig. 6 B  ). As indicated, although both WT and 
SOCS2-defi  cient DCs generated signifi  cant levels of 15-epi-LX 
after ASA treatment, COX1-defi  cient mice presented a sig-
nifi  cant delay with low levels of the eicosanoid (Fig. S10 B). 
This fi  nding suggests that COX1-derived prostanoids are re-
quired to establish the enzymatic pathways needed to pro-
duce 15-epi-LXA  4  , rather than direct involvement of COX1 
in the biosynthesis of 15-epi-LXA  4   in this system (for review 
see [  7  ]). ASA caused a SOCS2-dependent ablation of LPS-
induced TNF and IL-12p70 production (  Fig. 6 C  ), suggesting 
that ATL-induced SOCS2 regulates the LPS-driven signaling 
cascade in DCs by inhibiting I    B     degradation and abolish-
ing NF-    B signaling. In agreement with these observations, 
in vivo treatment with ASA led to TRAF2/TRAF6 poly-
ubiquitylation and degradation that could be prevented by 
pretreatment with PR11 (  Fig. 6, D and E  ). Such treatment 
(c) mortality occurring     45  –  50 d after inoculation (  Fig. 5 F  ).   
Interestingly, we found higher frequencies of IFN-      –  produc-
ing CD4  +   and CD8  +   T cells after in vitro recall stimulation 
(  Fig. 5, C and D  ), supporting our fi  ndings that proteasome 
inhibition not only did not inhibit T cell priming during 
infection, but enhanced it. Immunofl  uorescence analysis re-
vealed that SOCS2-dependent loss of TRAF2 and TRAF6 
expression in spleen and brain during   T. gondii   infection was 
    Figure 5.         In vivo proteasome inhibition abolishes the antiinfl  am-
matory actions of LX-induced SOCS2: modulation of proinfl  amma-
tory response during infection.   (A) WT and SOCS2-defi  cient mice (  n   = 
10/group) were infected intraperitoneally with   T. gondii  , and treated with 
PBS (0.2 ml/mouse) or PR11 (0.2 mg/kg) every other day, from 11 to 27 d 
after infection. Serum concentrations of IL-12 p70 (A) and IFN-     (B)  were 
quantifi  ed by ELISA 15 d after infection. At the same time point, mice 
were killed, spleens were harvested, and cell suspensions were prepared 
and incubated with PBS or STAg (100 ng/ml) for 4 h, followed by fl  ow 
cytometric quantifi  cation of intracellular IFN-     in  CD4 +   (C) and CD8  +  
T cells (D). 30 d after infection, the number of brain cysts was determined 
by microscopy (E). Mortality curves were monitored (F). (G) Spleens were 
removed from mice 30 d after infection. Frozen sections of spleens were 
processed and for in situ detection of SOCS2 (I  –  VI), TRAF2 (I, III and V), 
and TRAF6 (II, IV and VI) specifi  c primary antibodies were used, followed 
by a secondary antibody anti-IgG Alexa Fluor 488 (green) and anti-IgG 
Alexa Fluor 594 (red), and the cells were counterstained with DAPI. Images 
were captured using an Axiovert microscope with AxioVision software 
(see Materials and methods). CT, uninfected control; Tg,   T. gondii -infected. 
Graphed values represent the means   ±   the SD. The experiments shown 
are representative of at least two independent experiments yielding simi-
lar results. Bars, 50   μ  m.     JEM VOL. 205, May 12, 2008 
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    Figure 6.         The antiinfl  ammatory actions of ATLs require SOCS2-dependent proteasomal degradation of TRAF2 and TRAF6.   (A) WT and SOCS2-
defi  cient mice (  n   = 10 mice/group) were treated orally with ASA (5 mg/kg), or PBS as a control. 45 min later, splenic DCs were purifi  ed and stimulated 
with LPS (1   μ  g/ml) or medium alone. At the indicated times, TRAF2, TRAF6, ERK2, p38, JNK2, I   B   , pJNK, pERK1/2, pP38, and actin expression were quan-
tifi  ed as indicated in   Fig. 2  . (B) Splenic DCs purifi  ed from WT, SOCS2-defi  cient, and COX1-defi  cient mice were incubated in the absence or presence of 
5 mM ASA for 0, 30, or 90 min, followed by quantifi  cation of actin, TRAF6, and SOCS2 expression by Western blot. (C) Splenic DCs, purifi  ed from WT and 
SOCS2-defi  cient mice that had been treated with ASA or PBS as in A, were stimulated with LPS (1   μ  g/ml) or PBS. After overnight culture, IL-12p70 and 
TNF secretion was quantifi  ed in by ELISA. (D) Splenic DCs purifi  ed from WT and SOCS2-defi  cient mice that had been treated with ASA or PBS as in A un-
derwent Western blot analysis of polyubiquitylated TRAF2 and TRAF6, as indicated in   Fig. 2  . (E and F) WT and SOCS2-defi  cient mice were injected intra-
peritoneally with 0.2 mg/Kg PBS or PR11, followed by PBS or ASA treatment. 1 h later, splenic DCs were purifi  ed and whole-cell extracts underwent 
immunoblot analysis to quantify TRAF2 and TRAF6 expression (E). WT and SOCS2-defi  cient mice were injected intraperitoneally with PR11 (or PBS), fol-
lowed by ASA (or PBS). 45 min later, mice were challenged intraperitoneally with LPS (5   μ  g/mouse). 3 h later, serum TNF concentrations were quantifi  ed 
by ELISA (F). (G  –  O) WT (G, I, K, and M) and SOCS2-defi  cient (H, J, L, and N) DCs, purifi  ed from PBS-treated (F  –  I) or ASA-treated (J  –  M) mice, were incubated 
for 45 min with PBS (G, H, K, and L) or LPS (1   μ  g/ml; I, J, M, and N), and then cytospun onto slides. DCs subsequently underwent immunofl  uorescence 
staining for TRAF6 (green) and p65 (red), followed by counterstaining with DAPI (blue). Microphotographs were taken using an Axiovert microscope with 
AxioVision software (see Materials and methods). (O) Nuclear extracts were prepared and the levels of DNA-bound p65 quantifi  ed using an NF-   B  p65 
Transcription Factor Assay kit. Data shown are the mean   ±   the SD of triplicate samples, and are representative of three independent experiments with 
similar results. *, P   <   0.01, PR11 or ASA versus PBS treatment. Bars, 2   μ  m.     1084 TRAF2 AND TRAF6 PROTEASOMAL DEGRADATION BY LIPOXIN-INDUCED SOCS2 | Machado et al.
tors such as the TLRs (  28  –  31  ), responding by secreting cyto-
kines important in immune activation and specifi  cation of 
the class of immune response. During infection with   T. gondii   
(and infection with diverse other intracellular pathogens), 
DC production of IL-12, IFN-    , and TNF is essential in 
controlling pathogen growth (  32  –  34  ). IL-12 and TNF are 
potentially toxic when produced in excess, and their produc-
tion is known to be carefully regulated by a remarkably large 
number of diff  erent mechanisms (  26, 29, 32  ). In toxoplasmo-
sis, the proinfl  ammatory process is counterbalanced by the si-
multaneous induction of critical, nonredundant counterregu-
latory mediators, including IL-10 and LXs (  32, 33  ). Mice 
with a genetic defi  ciency in LX production succumb to lethal 
infl  ammatory responses during toxoplasmosis. In turn, the 
biological importance and nonredundant nature of the prote-
asome pathway to the mechanism of action of LXs is under-
scored by the fi   nding that proteasome inhibition during 
toxoplasmosis prevents the regulatory actions of LX, restor-
ing TLR and cytokine receptor signaling in vivo and causing 
uncontrolled proinfl  ammatory cytokine production, aberrant 
leukocyte infi  ltration and elevated mortality. 
  Since its fi  rst chemical synthesis and clinical trials in the 
late 19th century, the cellular and molecular mechanisms of 
action of ASA have been the focus of intense research (  35  ). 
In the early 1970s, a series of reports by J.R. Vane established 
that ASA and ASA-like drugs inhibit prostaglandin synthesis 
(  36  ). For the next 20 yr, this was the dominant view for the 
overall mechanism of action of ASA, despite the fi  nding that 
at the cellular level, ASA inhibits neutrophil activation, even 
in the presence of cyclooxygenase products (  37  ). Claria and 
Serhan (  38  ) showed that, in the presence of ASA, cyclooxy-
genase-2 is acetylated, yet remains active and converts arachi-
donic acid into intermediates that are converted into potent 
ATL, thus opening the possibility that ATLs are indeed me-
diating the antiinfl  ammatory actions of ASA in vivo. Indeed, 
ATLs display powerful pro-resolution and antiinfl  ammatory 
actions in several cell types and disease settings (  27  ). This new 
body of evidence sheds light on the possible intracellular 
pathways that are controlled by ASA and ATLs. ASA has 
been shown to inhibit neutrophil and macrophage activation, 
calcium fl  ux, and integrin activation, as well as IL-12, TNF, 
and IL-8 production (  27  ), suggesting that the downstream 
inhibition targets are critical elements of a general proinfl  am-
matory pathway. In agreement with this hypothesis, it was 
shown that ASA blocks NF-    B activation and nuclear trans-
location (  39  ). Our earlier observation that ATL-induced 
SOCS2 mediated some of the antiinfl  ammatory actions of 
ASA (9) opened the possibility of exploring novel intracellu-
lar mechanisms of action of this drug. The results presented 
in this study clearly indicate that TRAF6 is a key molecular 
target of ASA and that proteasome-mediated degradation of 
TRAF6 plays an important role and is a major infl  ammation 
resolution pathway up-regulated by ASA. In a similar vein, 
Paul-Clark et al. recently demonstrated that 15-epi-LXA  4   
mediates ASA induction of nitric oxide, negatively regulat-
ing leukocyte-endothelium interactions (  40  ). What role this 
also abolished SOCS2-dependent inhibition of in vivo LPS-
induced TNF production (  Fig. 6 F  ) and thioglycollate-stimu-
lated neutrophil migration (Fig. S10, C and D). 
  To further evaluate ATL-induced, SOCS2-mediated in-
hibition of NF-    B activation, we correlated NF-    B localiza-
tion with DNA-binding activity. As shown in   Fig. 6 (G  –  O)  , 
LPS treatment caused nuclear translocation of NF-    B p65, 
something prevented by ASA pretreatment in a SOCS2-
dependent manner. NF-    B p65 DNA-binding activity paral-
leled its nuclear translocation (  Fig. 6 O  ); similar fi  ndings were 
obtained for NF-    B p50 (Fig. S11, available at http://www
.jem.org/cgi/content/full/jem.20072416/DC1). Thus, the anti-
infl  ammatory eff  ects of ASA on DCs is mediated by SOCS2-
dependent proteasomal degradation of TRAF2/TRAF6. 
    DISCUSSION   
  Immunologists have traditionally focused on the mechanisms 
that underlie and control the activation of infl  ammatory 
responses. The last decade has seen growing awareness and 
experimental attention paid to the fact that restraint and reso-
lution of infl  ammatory responses is also, perforce, under tight, 
active regulation. In turn, this has led to growing interest in 
facilitation of resolution (as opposed to inhibition of activa-
tion) as a therapeutic strategy for the dysregulated infl  am-
mation seen as central to the pathogenesis and expression 
of an increasingly wide spectrum of diseases (  27  ). Therapeutic 
harnessing of the multilevel, resolution-promoting bioactivities 
of the LXs, and novel resolution mediators such as the D- and 
E-series resolvins and protectins, is thus quite attractive. 
  The mechanisms of action of the LXs, at the level of cel-
lular signaling, are of interest. Along these lines, LXA  4   and 
ATL restrain innate and acquired immune responses via stim-
ulating SOCS2 expression in an AhR-dependent manner (  9  ). 
The current studies elucidate new molecular targets and 
mechanism of action of LX/ATL-induced SOCS2. Specifi  -
cally, these results indicate that: (a) LX-induced SOCS2 tar-
gets TRAF2 and TRAF6 for proteasomal degradation; (b) 
degradation of TRAF6 renders cells exposed to LX unable to 
respond to stimulation through TLRs, TNF-R, IL-1R, and 
CD40, resulting in the inhibition of proinfl  ammatory cyto-
kine production by DCs; (c) proteasome-mediated degrada-
tion of TRAF6 plays a major role in the mechanism of action 
of ASA in restraining DC production of proinfl  ammatory 
cytokines; and (d) this pathway of targeted proteasomal deg-
radation of signaling intermediates is critical for successful 
modulation of infl  ammatory responses during infection with 
the ubiquitous protozoan pathogen,   T. gondii  . The biological 
role of LX- and ASA-driven TRAF2 degradation remains to 
be defi  ned. 
  A fundamental question in host  –  pathogen interactions is 
whether the immune system is properly activated to eradicate 
the pathogens, and whether this response is appropriately 
controlled to prevent damage to the host during control or 
elimination of infection. Microbial recognition is a critical 
fi  rst step. Central to both innate and adaptive immunity, DCs 
signal the presence of microbes via pattern recognition recep-JEM VOL. 205, May 12, 2008 
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  DNA transfection.     10  7   RAW 264.7 (or HL60) cells were transfected as 
previously described (  42  ) with 10   μ  g of mTRAF6 (Invivogen), fl  ag-tagged 
mTRAF2, fl  ag-tagged mTRAF3, or the respective control plasmids. To de-
termine transfection effi   ciency, all cells were also transfected with pMaxGFP 
plasmid (Amaxa). Cells were then plated in 24-well plates in RPMI (supple-
mented with 10% FCS,   l-  glutamine, and gentamycin). 20 h after transfec-
tion, cells were exposed to LXA  4   or vehicle control and incubated for a 
further 24 h before stimulation with LPS, CD40L, TNF, or STAg. Cells and 
supernatants were harvested 24 h after stimulation and analyzed for GFP ex-
pression (FACS), IL-12 expression (ELISA), and expression of the trans-
fected proteins (Western blot). 
  Statistical analysis.     The statistical signifi  cance of diff  erences in mean values 
between experimental versus control or vehicle-treated samples was evalu-
ated by means of Student  ’  s   t   test. Diff  erences were considered to be signifi  -
cant at P   <   0.05. 
  Online supplemental material.     Fig. S1 shows that TRAF2 and TRAF6 
are molecular targets for LX-mediated, SOCS2-dependent inhibition of 
TLR and TNFR family signaling. Fig. S2 shows that late in vivo treatment 
with PR11 during LCMV infection does not aff  ect the priming of LCMV-
specifi  c CD8+ T cells. Fig. S3 shows the cytokine expression in the presence 
of proteasome inhibition during infection with   T. gondii  . Figs. S4-9 shows 
the in situ immunofl  uorescence analysis of SOCS2 induction, TRAF2 and 
TRAF6 expression, and pro-infl  ammatory gene expression after proteasome 
inhibition during   T. gondii   infection of WT and SOCS2-defi  cient mice. Fig. 
S10 shows that proteasome inhibition blocks ATL-induced SOCS2 antiin-
fl  ammatory actions in vivo. Fig. S11 shows that ASA-induced SOCS2 tar-
gets TRAF2 and blocks p50 and p65 translocation to the nucleus after LPS 
stimulation. The online version of this article is available at http://www
.jem.org/cgi/content/full/jem.20072416/DC1. 
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pathway plays in modulating DC function is currently under 
active investigation. 
  It has become clear in recent years that dysregulated in-
fl  ammatory responses are central to the pathogenesis of a wide 
range of diseases, causing an enormous burden of morbidity 
and mortality in the world at large. The results presented in this 
study suggest that degradation of TRAF6 provides a promising 
biochemical target for drug development aimed at modulating 
infl  ammatory processes in these diseases. 
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